1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Daehan Nupharm Co., Ltd.

Daehan Nupharm Co., Ltd.

KKRX:054670
5,190.00
KRW
+20.00
(+0.39%)
1,116.99EPS
6.28P/E
98.39BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3,944.59
5,108.83
6,417.32
7,793.4
9,318.19
8,474.13
9,547.47
10,636.33
11,867.35
14,107.71
14,557.21
14,404.57
14,419.75
14,633.78
Basic EPS, GAAP
-136
189
295
-404
-1,466
174
1,085
-721
1,118
1,733
894
1,102
1,087
1,116.99
Free Cash Flow per Basic Share
-25.31
222.31
272.58
275.16
-313.52
1,320.1
966.3
266.48
420.47
764.37
178.1
-1,092.79
-3,277.75
-3,000.05
Dividend per Share
- -
- -
- -
- -
49.99
- -
- -
- -
- -
80.02
100.05
99.99
99.99
100
Book Value per Share
5,104.8
5,264.39
5,500.56
5,073.12
3,685.05
3,069.4
4,350.9
4,220.71
5,875.57
7,335.72
7,791.5
8,937.39
9,971.21
9,847.32
Tangible Book Value per Share
4,899.76
5,033.22
5,294.49
4,948.62
3,596.4
3,015.6
4,331.79
4,194.37
5,845.39
7,311.77
7,751.32
8,857.49
9,854.56
9,767.98
Basic Weighted Avg Shares
14
14
14
14
14
14
14
14
14
14
14
14
14
14
Sales/Revenue/Turnover
56,702
71,940
90,230
109,403
130,816
119,528
134,097
149,293
166,586
197,957
204,223
202,187
202,401
205,389
Operating Margin (%)
10.52
10.99
11.12
10.55
10.02
16.75
15.44
11.11
15.5
18.43
9.21
9.23
5.79
5.17
Depreciation Expense
1,639
2,145
2,967
3,872
3,193
3,125
3,588
3,027
3,330
3,228
3,481
4,098
4,302
4,380
Net Income, GAAP
-1,955
2,661
4,148
-5,671
-20,581
2,454
15,239
-10,120
15,694
24,317
12,542
15,468
15,258
15,677
Effective Tax Rate (%)
209.65
26.4
37.75
- -
4,169.18
68.29
22.89
- -
33.45
29.56
39.36
15.82
- -
- -
Profit Margin (%)
-3.45
3.7
4.6
-5.18
-15.73
2.05
11.36
-6.78
9.42
12.28
6.14
7.65
7.54
7.63
Working Capital
3,792
2,125
12,920
28,535
10,979
9,232
16,426
17,583
30,984
44,058
36,727
43,473
40,523
43,017
LT Debt
1,452
429
7,742
13,076
12,757
9,827
8,645
9,462
15,966
2,232
369
19,241
54,492
58,822
Total Equity
71,647
73,887
77,202
71,203
51,721
43,080
61,066
59,239
82,465
102,959
109,356
125,439
139,949
138,210
Return on Invested Capital (%)
-5.81
5.19
5.63
- -
-527.93
7.16
17.91
- -
16.41
15.03
8.06
9.56
- -
- -
Return on Capital (%)
-5.27
4.09
4.79
- -
-80.35
3.36
18.13
- -
14.96
19.46
9.53
10.25
- -
- -
Return on Common Equity (%)
-2.8
3.66
5.49
-7.64
-33.49
5.18
29.27
-16.82
22.15
26.23
11.81
13.18
11.5
11.85

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
43,992
44,465
48,729
LT Borrowings
50,298
54,087
58,500
LT Finance Leases
324
405
322
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
96,422
92,212
98,387

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
109,146
113,893
118,820
Cash, Cash Equivalents & STI
31,077
33,003
33,383
Accounts Receivable, Net
33,519
31,333
32,270
Inventories
37,028
41,076
42,151
Total Current Liabilities
67,909
73,371
75,803
Payables & Accruals
- -
- -
- -
ST Debt
43,992
44,465
48,729
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.35%
19.31%
11.57%
Free Cash Flow
-128.69%
-90.23%
199.95%
Net Income, GAAP
4.22%
-45.32%
-1.36%
Sales/Revenue/Turnover
8.84%
6.54%
0.11%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,260
54,138
48,810
50,979
202,187
2025
51,855
49,873
48,884
51,790
202,401
2026
54,843
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
372
399
140
191.17
1,102
2025
184
214.3
185.87
503.23
1,087
2026
213.59
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
100.07
- -
- -
- -
99.99
2025
100.17
- -
- -
- -
99.99
2026
100
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Won-Seok Lee
Full Time Employees
393
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Hwaseong-si South Korea
IPO Date
Feb 26, 2002
Website
dhnp.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Daehan Nupharm Co., Ltd. is a South Korea-based healthcare and life sciences company engaged primarily in the research, development, manufacturing, and commercialization of human pharmaceuticals, veterinary healthcare products, medical aesthetics, and bio-wellness solutions. Founded in 1984 and headquartered in Hwaseong, South Korea, the company operates across four key business divisions: Human Pharmaceuticals, Animal Health, Bio-Aesthetics and Wellness, and Contract Manufacturing (CMO/CDMO) Services. In its human pharmaceutical division, the company manufactures and distributes prescription drugs (ETC) and over-the-counter (OTC) medications, specializing in anti-obesity and metabolic syndrome therapies; cardiovascular and circulatory agents; gastrointestinal treatments; musculoskeletal, anti-inflammatory, and analgesic formulations; central nervous system and respiratory remedies; anti-infectives; and specialized wellness injectables, including thioctic acid, glutathione, ascorbic acid, and placenta extract formulations. In its animal health segment, the company develops and supplies veterinary therapeutics, vaccines, anthelmintics, antibiotics, immune modulators, nutritional supplements, and functional feed additives designed for livestock, poultry, swine, aquaculture, and companion animals. In its bio-aesthetics and wellness division, the company offers hyaluronic acid dermal fillers, polydioxanone (PDO) lifting threads, mesotherapy solutions, skin boosters, functional cosmeceuticals, and health functional foods. The company operates advanced KGMP-compliant production facilities in the Hyangnam Pharmaceutical Complex and distributes its portfolio domestically to hospitals, clinics, pharmacies, and livestock enterprises, while exporting to international markets across Southeast Asia, Central Asia, Latin America, and the Middle East. In recent strategic developments, Daehan Nupharm has expanded its automated injectable production capacities and modernized its manufacturing infrastructure to strengthen its high-margin global CDMO business; broadened its aesthetic and companion animal pipelines through the introduction of premium skin rejuvenation formulations and specialized pet therapeutics; and secured targeted international distribution partnerships to accelerate market penetration and regulatory registrations in high-growth emerging economies.